Motoneuron-specific NR3B gene: no association with ALS and evidence for a common null allele.
Niemann S, Landers JE, Churchill MJ, et al. Motoneuron-specific NR3B gene: no association with ALS and evidence for a common null allele. Neurology 2008;70:666-676.
Motoneuron-specific expression of NR3B, a novel NMDA-type glutamate receptor subunit that works in a dominant-negative manner.
Nishi M, Hinds H, Lu HP, et al. Motoneuron-specific expression of NR3B, a novel NMDA-type glutamate receptor subunit that works in a dominant-negative manner. J Neurosci 2001;21:RC185.
Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice.
Guo H, Lai L, Butchbach MER, et al. Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet 2003;12:2519-2532.
A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice.
Kieran D, Hafezparast M, Bohnert S, et al. A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. J Cell Biol 2005;169:561-567.
The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis.
Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta 2006;1762:1068-1082.
Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data.
Schymick JC, Schalz SW, Fung HC, et al. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol 2007;6:322-328.